Encodes An Animal Polypeptide Patents (Class 536/23.5)
-
Publication number: 20140113285Abstract: A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.Type: ApplicationFiled: May 22, 2013Publication date: April 24, 2014Applicants: Centre National de la Recherche Scientifique, Institut PasteurInventors: Christine PETIT, Francoise Denoyelle-Gryson, Dominique Weil, Sandrine Marlin-Duvernois, Jean-Luc Guesdon
-
Publication number: 20140113330Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: ApplicationFiled: December 9, 2013Publication date: April 24, 2014Applicant: Regents of the university of MinnesotaInventor: Gary L. Nelsestuen
-
Publication number: 20140113959Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.Type: ApplicationFiled: December 16, 2013Publication date: April 24, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140113960Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.Type: ApplicationFiled: December 16, 2013Publication date: April 24, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Patent number: 8703927Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: July 5, 2012Date of Patent: April 22, 2014Assignee: Acceleron Pharma Inc.Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
-
Publication number: 20140107020Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140107034Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: ZymoGenetics, Inc.Inventors: Carl W. BIRKS, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
-
Publication number: 20140105855Abstract: IL-17 Receptor binding proteins, including non-naturally occurring and recombinantly modified proteins, methods of making and using such molecules as therapeutic, prophylactic and diagnostic agents are provided.Type: ApplicationFiled: April 6, 2012Publication date: April 17, 2014Inventor: Kenan Christopher Garcia
-
Publication number: 20140106352Abstract: Isolated nucleotides encoding polypeptides with mutations leading to amino acid substitutions linked to hereditary kidney disease or malformation of the urinary tract are provided herein. Constructs, cells, probes and inhibitory molecules comprising these mutations are also provided and may be used in screening assays for candidate agents to treat or reverse these diseases or alternatively to provide diagnostic tests. Methods of diagnosing subjects likely to develop these diseases or to be carriers of these diseases are also provided.Type: ApplicationFiled: October 2, 2013Publication date: April 17, 2014Applicant: Duke UniversityInventors: Rasheed A. Gbadegesin, Michelle P. Winn
-
Publication number: 20140106345Abstract: Novel peptides, their derivatives and compositions including the same for their use as a tool in prognosis or diagnosis of a grafted organ distress, notably of graft or transplant rejection.Type: ApplicationFiled: May 24, 2012Publication date: April 17, 2014Applicant: BIOVIALIFE INC.Inventor: Félix Agbalika
-
Publication number: 20140105964Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 11, 2013Publication date: April 17, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140105965Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 12, 2013Publication date: April 17, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140107189Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.Type: ApplicationFiled: December 16, 2013Publication date: April 17, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140105896Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140105898Abstract: This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists, including nucleic acids such as TRAIL polynucleotides, peptides and polypeptides including TRAIL polypeptides, TRAIL DR agonist antigen-binding molecules, TRAIL DR peptide agonists as well as small molecule TRAIL DR agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome.Type: ApplicationFiled: February 27, 2012Publication date: April 17, 2014Applicant: Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo GaroInventors: Merlin C. Thomas, Giorgio Zauli, Paola Secchiero, Bruno Fabris, Stella Bernardi
-
Patent number: 8697655Abstract: Provided is a peptide including the following amino acid sequence. Tyr-Xaa0-Xaa1-Tyr-Tyr-Xaa2-Xaa3-Tyr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 (SEQ ID NO: 4: wherein Xaa0, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 and Xaa 11 represent any amino acid) or Tyr-Asn-Asp-Tyr-Tyr-Tyr-Tyr-Cys-Tyr-Arg-Asp-Tyr-Asp (SEQ ID NO: 20).Type: GrantFiled: September 10, 2012Date of Patent: April 15, 2014Assignee: RikenInventors: Akira Wada, Yoshihiro Ito, Takashi Kitajima
-
Patent number: 8697854Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: November 24, 2009Date of Patent: April 15, 2014Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbHInventors: Dolores Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Patent number: 8697836Abstract: Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.Type: GrantFiled: April 25, 2008Date of Patent: April 15, 2014Assignee: The Regents of the University of CaliforniaInventor: Maurizio Zanetti
-
Patent number: 8697650Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: GrantFiled: February 15, 2011Date of Patent: April 15, 2014Assignee: Medimmune, LLCInventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
-
Publication number: 20140099641Abstract: The present invention relates to primer sets for diagnosing ankylosing spondylitis and the method for diagnosing ankylosing spondylitis using the same. Particularly, the present invention provides primer sets for diagnosing ankylosing spondylitis as follows: (a) a primer set comprising a primer having at least 95% sequence homology with SEQ ID NO: 7, and at least one primer selected from the group consisting of primers of SEQ ID NOs: 9 to 13; (b) a primer set comprising at least one primer selected from the group consisting of primers of SEQ ID NOs: 15 to 17, and a primer having at least 95% sequence homology with SEQ ID NO: 19 and (c) a primer set comprising a primer having at least 95% sequence homology with SEQ ID NO: 18, and a primer having at least 95% sequence homology with SEQ ID NO: 20. The primer sets and the kit for diagnosing ankylosing spondylitis of the present invention can be effectively used for early diagnosis. tracking progress and prognosis of ankylosing spondylitis.Type: ApplicationFiled: January 6, 2011Publication date: April 10, 2014Applicant: KIST-EUROPE FGMBHInventors: Chang Hoon Nam, Yeon Joo Kim, Han-Joo Back
-
Publication number: 20140099280Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.Type: ApplicationFiled: February 24, 2012Publication date: April 10, 2014Applicant: Cenre National De La Recherche ScientifiqueInventors: Jean-Philippe Girard, Corinne Cayrol-Girard, Emma Lefraancais
-
Publication number: 20140099699Abstract: A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that the domains are mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID NOs: 2 and that the TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a reference TCR. Embodiments of the invention such as the use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described.Type: ApplicationFiled: July 22, 2013Publication date: April 10, 2014Applicant: IMMUNOCORE LIMITEDInventors: Bent Karsten Jakobsen, Naomi Harwood, Nathaniel Ross Liddy
-
Publication number: 20140099315Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.Type: ApplicationFiled: December 12, 2013Publication date: April 10, 2014Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
-
Publication number: 20140099284Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.Type: ApplicationFiled: October 14, 2011Publication date: April 10, 2014Applicant: EOS NEUROSCIENCE, INCInventors: Alan Horsager, Andrew Smith, Benjamin C. Matteo
-
Publication number: 20140099334Abstract: The invention relates to epitopes of SEMA4D and to binding agents, such as antibodies, that specifically bind to SEMA4D.Type: ApplicationFiled: March 14, 2013Publication date: April 10, 2014Applicant: VACCINEX, INC.Inventor: VACCINEX, INC.
-
Publication number: 20140099310Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: August 6, 2013Publication date: April 10, 2014Applicant: CELERA CORPORATIONInventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Patent number: 8691242Abstract: The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection.Type: GrantFiled: September 13, 2010Date of Patent: April 8, 2014Assignee: Absynth Biologics LimitedInventors: Jorge Garcia Lara, Simon Foster
-
Publication number: 20140094586Abstract: An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learnig method.Type: ApplicationFiled: March 15, 2013Publication date: April 3, 2014Applicants: KOCHI UNIVERSITY, NEC CORPORATIONInventors: NEC Corporation, Kochi University
-
Publication number: 20140093956Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: IMMUNEX CORPORATIONInventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
-
Publication number: 20140093531Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicants: Fundacao Oswaldo Cruz (FIOCRUZ), The Government of the United States of America as represented by the Secretary of the Department ofInventors: Jesus G. Valenzuela, Jose M.C. Ribeiro, Aldina Barral, Manoel Netto, Claudia I. Brodskyn, Regis Gomes
-
Publication number: 20140096274Abstract: The present invention relates to variants of TNF family ligands which have been mutated at the ligand trimerisation interface so that they are not capable of assembling into trimers, and either assemble into dimers or remain as monomers. Such ligands bind to the TNF receptor but are unable to activate it, effectively functioning as competitive inhibitors. The invention also relates to nucleic acids encoding the variants of TNF family ligands, vectors and host cells comprising the nucleic acid and methods for the treatment of diseases associated with aberrant signalling through a TNF receptor.Type: ApplicationFiled: December 23, 2011Publication date: April 3, 2014Inventors: Wilhelmus Johannes Quax, Vicente R. Tur, Luis Serrano, Albert Martinus Van Der Sloot, Robbert H. Cool, Aart H.G. Van Assen
-
Publication number: 20140094416Abstract: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.Type: ApplicationFiled: November 12, 2013Publication date: April 3, 2014Applicant: Abraxis BioScience, LLCInventors: Vuong Trieu, Daniel Knauer, Neil Desai
-
Publication number: 20140093872Abstract: A method of detecting mutation in blood cell-free DNA, includes providing a serum sample, isolating DNA from the serum sample, amplifying the DNA by polymerase chain reaction (PCR), subjecting the PCR product to primer extension (PE), and separating the PE reaction product and identifying the mutation by gel electrophoresis. In order to improve accuracy and sensitivity, the PE reaction can be carried out by using a primer that blocks the extension of the wild or non-mutated sequence.Type: ApplicationFiled: March 11, 2013Publication date: April 3, 2014Applicant: U.S. Department of Veterans AffairsInventor: Ovidiu PLATICA
-
Publication number: 20140094384Abstract: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.Type: ApplicationFiled: November 25, 2013Publication date: April 3, 2014Applicant: Georgetown UniversityInventors: David SOLOMON, Jung-Sik Kim, Todd Waldman
-
Publication number: 20140093524Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.Type: ApplicationFiled: August 19, 2013Publication date: April 3, 2014Applicant: INVION LimitedInventors: Dean Jason TAYLOR, Barbara Jane JOHNSON, Caroline Amanda Dobbin, Christopher Bruce HOWARD, Linda Allison WARD
-
Patent number: 8685929Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.Type: GrantFiled: April 10, 2012Date of Patent: April 1, 2014Assignee: The Regents of the University of CaliforniaInventors: Donna G. Albertson, Daniel Pinkel, Colin Collins, Joe W. Gray, Bauke Ylstra
-
Publication number: 20140087416Abstract: The present invention relates to methods and compositions for use in generating induced hepatocytes by reprogramming non-hepatocyte cells.Type: ApplicationFiled: September 6, 2013Publication date: March 27, 2014Applicant: Genentech, Inc.Inventors: Kamen P. Simeonov, Hirdesh Uppal
-
Publication number: 20140086924Abstract: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.Type: ApplicationFiled: April 12, 2013Publication date: March 27, 2014Inventor: University of Massachusetts
-
Publication number: 20140088008Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.Type: ApplicationFiled: November 20, 2013Publication date: March 27, 2014Applicant: Amgen Inc.Inventors: Huiquan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20140086943Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: March 15, 2013Publication date: March 27, 2014Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Peter LEWANDROWSKI, Oliver SCHOOR
-
Patent number: 8679749Abstract: Polynucleotides encoding variant polypeptides of DsRed are provided herein. The DsRed variants have increased bacterial expression, reduced aggregation, increased solubility, shifted emission spectra or increased brightness relative to a wild-type DsRed.Type: GrantFiled: November 3, 2008Date of Patent: March 25, 2014Assignee: The University of ChicagoInventors: Benjamin S. Glick, Daniel E. Strongin, Robert Keenan, Rita L. Strack, Dibyendu Bhattacharyya
-
Publication number: 20140080177Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: August 20, 2013Publication date: March 20, 2014Applicant: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 8673850Abstract: A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.Type: GrantFiled: June 1, 2009Date of Patent: March 18, 2014Assignee: Institut de Recherches Cliniques de MontrealInventors: Nabil G. Seidah, Gaétan Mayer, Steve Poirier
-
Patent number: 8673855Abstract: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases.Type: GrantFiled: June 8, 2010Date of Patent: March 18, 2014Assignee: Seoul National University R&DB FoundationInventors: Vic Narry Kim, Jung Hyun Lee
-
Patent number: 8673268Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.Type: GrantFiled: January 5, 2012Date of Patent: March 18, 2014Assignee: Galapagos N.V.Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
-
Publication number: 20140072973Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described.Type: ApplicationFiled: September 12, 2013Publication date: March 13, 2014Inventors: B. Maria H. Eriksson, Francis S. Collins, Leslie B. Gordon, William Ted Brown
-
Publication number: 20140072565Abstract: The present invention relates to a novel epitope to convert T cell to type 17 helper T (TH17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method, for enhancing immunity using the antibody.Type: ApplicationFiled: April 12, 2013Publication date: March 13, 2014Applicant: National Cancer CenterInventor: National Cancer Center
-
Publication number: 20140073557Abstract: A novel approach for inhibiting FGF2/FGFR1-mediated signalling is presented which is based on FGFR1 mutations to introduce higher affinity for the natural GAG co-receptors into the soluble part of the FGF1 receptor, preferably into the D2/D3 domains.Type: ApplicationFiled: March 16, 2012Publication date: March 13, 2014Applicant: PROTAFFIN BIOTECHNOLOGIE AGInventors: Andreas Kungl, Martina Theuer
-
Publication number: 20140072970Abstract: A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described.Type: ApplicationFiled: May 24, 2013Publication date: March 13, 2014Applicant: The Hospital for Sick ChildrenInventors: Stephen W. Scherer, Berge A. Minassian
-
Publication number: 20140073572Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.Type: ApplicationFiled: October 1, 2013Publication date: March 13, 2014Applicants: MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body CorporateInventors: Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer